HR5160Referred to Committee

Stem Cell Therapeutic and Research Reauthorization Act of 2025

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-09-04
Introduced
21
Cosponsors
HR
Type

Sponsor

Christopher H. Smith
Christopher H. Smith
Republican · NJ · Representative
Votes with party: 96.0% (602 recorded votes)

Full profile: /officials/S000522

Source: Congress.gov · FEC

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Placed on the Union Calendar, Calendar No. 629.

2026-07-02

Source: Congress.gov

Committee Activity

Currently in

Previously

Plain-English Summary

Stem Cell Therapeutic and Research Reauthorization Act of 2025 This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA). The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.

Plain-English rewrite of the Congressional Research Service summary published on Congress.gov. Cached and reviewed.

Subjects

Health

Full Bill Text

Verbatim text published on Congress.gov via GovInfo. Use Cmd+F / Ctrl+F to search within this excerpt.

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [H.R. 5160 Introduced in House (IH)] <DOC> 119th CONGRESS 1st Session H. R. 5160 To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes. _______________________________________________________________________ IN THE HOUSE OF REPRESENTATIVES September 4, 2025 Mr. Smith of New Jersey (for himself, Ms. Matsui, Mr. Bilirakis, Ms. Pingree, Ms. Tenney, and Mr. Mfume) introduced the following bill; which was referred to the Committee on Energy and Commerce _______________________________________________________________________ A BILL To reauthorize the Stem Cell Therapeutic and Research Act of 2005, and for other purposes. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Stem Cell Therapeutic and Research Reauthorization Act of 2025''. SEC. 2. REAUTHORIZATION OF THE C.W. BILL YOUNG CELL TRANSPLANTATION PROGRAM. Section 379B of the Public Health Service Act (42 U.S.C. 274m) is amended-- (1) by striking ``appropriated $31,009,000'' and inserting the following: ``appropriated-- ``(1) $31,009,000''; (2) in paragraph (1), as so inserted, by striking the period at the end and inserting ``; and''; and (3) by adding at the end the following: ``(2) $33,009,000 for each of fiscal years 2027 through 2031.''. SEC. 3. CORD BLOOD INVENTORY. Section 2(g) of the Stem Cell Therapeutic and Research Act of 2005 (42 U.S.C. 274k note) is amended by striking ``2026'' and inserting ``2031''. <all>